American pharmaceutical company unstoppable: money is flowing from consumer goods
Eli Lilly reported record revenues and profits in its second-quarter earnings report, while also raising its full-year revenue forecast. The strong results are attributed to the sustained high demand for its Zepbound and Mounjaro drugs. The stock price rose in pre-market trading, according to CNBC.
Eli Lilly reported record revenues and profits in its second-quarter earnings report, while also raising its full-year revenue forecast. The strong results are driven by robust demand for its Zepbound and Mounjaro drugs. The stock price is rising in pre-market trading, according to CNBC.
